Clinical trial
Role of Glucagon-Like Peptide-1 (GLP-1) in Congenital Hyperinsulinism: Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
NCT00835328 is registered in ClinicalTrials.gov with Diva De Leon as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Role of Glucagon-Like Peptide-1 (GLP-1) in Congenital Hyperinsulinism: Effect of Exendin (9-39) on Glucose Requirements to Maintain Euglycemia
- Lead sponsor
- Diva De Leon
- Phase
- Phase 1/2
- Overall status
- Terminated
- Start date
- August 26, 2009
- Completion date
- January 28, 2017
- Enrollment
- 14 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.